Furthermore the cries of how expensive it is for research and development for new drugs fail to include details of how much is spent on development of NEW drugs as opposed to ME TO drugs. Me To drugs are copies of drugs making money, already provided by other manufacturers and do not guarantee improvement in efficacy or safety of action.
The two examples below are to show 1. How GlaxoSmithKlyne made it clear they could pull out of the UK if pressure built up...and
2. how Pfizer is soon to be in court over their behaviour. One wonders how many people will be laid off if they are found guilty and have to face large fines.
If Pfizer takes over Astra Zeneca they could behave in the way GSK did before and the MHRA drugs regulator depends on the industry for funds. Hopefully all the MPs are not so naive as the Prime Minister appears to be.
This paper is published by the RCP available on the Internet and we have copied a small section below.